Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 4 1Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Gynecologic 1

Conditions

Overweight 1Obesity 1Neoplasms 1Endometrial Neoplasms 1Endometrial Hyperplasia 1

Interventions

Magnetic Resonance Spectroscopy 3Specimen Handling 2Papillomavirus Vaccines 2Lenalidomide 2Immune Checkpoint Inhibitors 2Imatinib Mesylate 2Human Papillomavirus Recombinant Vaccine nonavalent 2Diosmin 2Dexamethasone 2venetoclax 1trametinib 1tocilizumab 1sofosbuvir-velpatasvir drug combination 1semaglutide 1ruxolitinib 1rozanolixizumab 1rasburicase 1radium Ra 223 dichloride 1pyrotinib 1pirtobrutinib 1oxycodone-acetaminophen 1obinutuzumab 1nirogacestat 1nilotinib 1ixazomib 1idelalisib 1human papillomavirus vaccine, L1 type 16, 18 1fluciclovine F-18 1darolutamide 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Resistance Training × 30 days × Clear all
NCT07462663 2026-05-13

SHAPE-ENDO

Hospital Universitari de Bellvitge

Phase 4 Not yet recruiting
82 enrolled
GynecologicOther

Endometrial Hyperplasia, Neoplasms, Obesity, Endometrial Neoplasms, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡